We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 787

In Case Alleging Nationwide Pharmacy Fraud, Kmart Scores Narrow Settlement
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • April 25 2018

As described in an April 17, 2018 article originally posted on the Sheppard Mullin Richter and Hampton, LLP False Claims Act Defense Blog, Kmart


Health Plans and Pharmacy Benefit Managers - Past and Future
  • Sheppard Mullin Richter & Hampton LLP
  • USA
  • April 13 2018

Historically, health plans and pharmacy benefit managers (“PBMs”) have been uncomfortable neighbors. Plans provide drug coverage, but contract out the


Marijuana: Legal Framework in NJ for a Drug That is Illegal Under Federal Law: Reaction of US Attorneys to Rescission of Cole Memo
  • Porzio Bromberg & Newman PC
  • USA
  • February 6 2018

In the first part of our series, we outlined how the Department of Justice ("DOJ") during the Obama administration had provided specific guidance to


Marijuana: Creating a Legal Framework in New Jersey for a Drug That is Illegal Under Federal Law
  • Porzio Bromberg & Newman PC
  • USA
  • February 1 2018

Over the past several years, States have begun to legalize recreational marijuana. The first States to do so were Colorado and Washington in 2012


The Four Things That Surprised Us in the EpiPen False Claims Settlement
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • August 23 2017

On August 17, 2017, the U.S. Department of Justice (DOJ) announced that it had reached a $465 million false claims settlement with Mylan, the


The Latest in the Epipen Medicaid Drug Rebate Saga - Where Are We Now?
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • June 6 2017

The latest installment in the ongoing saga over EpiPen Medicaid Drug Rebates came on May 31, 2017, when Senator Charles Grassley issued a press


2016 False Claims Act Review: A Truly Extraordinary Year
  • Pietragallo Gordon Alfano Bosick & Raspanti LLP
  • USA
  • April 1 2017

As we head into the second quarter of an already turbulent 2017, it is worth reflecting on the truly extraordinary events of 2016. Of course, there


OIG Publishes Online Portfolio Highlighting its Body of Work on Drug Pricing and Reimbursement
  • Mintz Levin Cohn Ferris Glovsky and Popeo PC
  • USA
  • February 21 2017

On Friday February 17, 2017, the U.S. Department of Health and Human Services (HHS) Office of Inspector General (OIG) issued an Online Portfolio on


Midnight Madness The FDA Continues To Discount First Amendment Implications Of Restrictions On Off-Label Promotion
  • Reed Smith LLP
  • USA
  • January 27 2017

This guest post is from Liz Minerd, an associate at Reed Smith. She previously wrote the post on the FDA’s off-label promotion meeting last November


Medical Marijuana and the Workplace
  • Akerman LLP
  • USA
  • January 10 2017

With the growing list of states legalizing marijuana, are workplace drug policies up in smoke? As the new year begins, Arkansas, Florida and North